{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000024","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.075423+00:00","generated_at":"2026-06-04T14:52:03.643550+00:00","sec_items":["2.02","2.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neurogene reports FY2023 net loss $36.3M; Rett gene therapy trial expanded, cash runway to H2 2026","bullets":["Cash and investments $197.2M at Dec 31, 2023; reverse merger and $95M private placement completed December 2023.","FY2023 net loss $36.3M vs $55.2M prior year; Q4 net income $2.4M from $16.4M bargain purchase gain.","R&D expenses $44.4M (down from $47.5M), G&A $11.2M (up from $9.0M) due to reverse merger costs.","Phase 1/2 NGN-401 Rett syndrome trial expanded with high-dose Cohort 2; interim clinical data expected 4Q24.","Appointed Dr. Julie Jordan as CMO; CLN5 Batten disease trial interim data and regulatory update expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000024","json":"https://secwatch.observer/filing/0001404644-24-000024.json","markdown":"https://secwatch.observer/filing/0001404644-24-000024.md","text":"https://secwatch.observer/filing/0001404644-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/0001404644-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/ngne-20240318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:52:03.643550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70106125caa069ff61474e30d094c3969d33e390","claim":"Neurogene Inc. reported year ended December 31, 2023 results: net income net loss was $36.3 million for the twelve months ended December 31, 2023.","evidence_excerpt":"Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000024/0001404644-24-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Net income","value":"net loss was $36.3 million for the twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}